Literature DB >> 21921610

Renal-pulmonary crosstalk.

Kai Singbartl1.   

Abstract

Acute kidney injury (AKI) remains a major clinical challenge, especially in combination with acute lung injury (ALI). Clinical as well as experimental studies have provided evidence for clinically relevant kidney-lung interactions, ultimately leading to a drastic reduction in survival. The crosstalk between AKI and ALI is a consequence of both direct loss of normal organ function and inflammatory dysregulation resulting from each organ failure. Cellular (e.g. neutrophils) as well as soluble mediators (cytokines) contribute to the inflammatory dysregulation under these circumstances. Clinical interventions are currently limited to general, unspecific preventive or supportive measures. With respect to AKI, these strategies include adequate volume control, correction of acid-base/electrolyte abnormalities and elimination of uremic substances by renal replacement therapy. Lung protective ventilation, including low tidal volume ventilation, is a cornerstone in the management of ALI. This approach has been shown to attenuate both the direct mechanical effects of ventilation and the inflammatory response arising from ALI and mechanical ventilation, ultimately reducing the incidence of extrapulmonary organ failure. The fact that multiorgan failure is not only the sum of organ functions lost, but also includes inflammatory dysregulation together with a lack of treatment options greatly emphasizes the need for future research in this area.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2011        PMID: 21921610     DOI: 10.1159/000329237

Source DB:  PubMed          Journal:  Contrib Nephrol        ISSN: 0302-5144            Impact factor:   1.580


  9 in total

1.  Loss of matrix metalloproteinase-8 is associated with worsened recovery after ischemic kidney injury.

Authors:  Rajit K Basu; Emily Donaworth; Brian Siroky; Prasad Devarajan; Hector R Wong
Journal:  Ren Fail       Date:  2015-01-12       Impact factor: 2.606

2.  Regulation of the autophagy plays an important role in acute kidney injury induced acute lung injury.

Authors:  Ruolin Wang; Siheng Shen; Luyong Jian; Shuhua Liu; Qi Yuan; Huahui Guo; Jiasheng Huang; Penghui Chen; Renfa Huang
Journal:  Ren Fail       Date:  2022-12       Impact factor: 3.222

3.  Th17 cells contribute to pulmonary fibrosis and inflammation during chronic kidney disease progression after acute ischemia.

Authors:  Purvi Mehrotra; Jason A Collett; Susan J Gunst; David P Basile
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2017-11-14       Impact factor: 3.619

Review 4.  Kidney-lung cross-talk and acute kidney injury.

Authors:  Rajit K Basu; Derek S Wheeler
Journal:  Pediatr Nephrol       Date:  2013-01-20       Impact factor: 3.714

Review 5.  Heart-kidney crosstalk and role of humoral signaling in critical illness.

Authors:  Grazia Virzì; Sonya Day; Massimo de Cal; Giorgio Vescovo; Claudio Ronco
Journal:  Crit Care       Date:  2014-01-06       Impact factor: 9.097

6.  Associations between single nucleotide polymorphisms in the FAS pathway and acute kidney injury.

Authors:  Pavan Bhatraju; Christine Hsu; Paramita Mukherjee; Bradford J Glavan; Amber Burt; Carmen Mikacenic; Jonathan Himmelfarb; Mark Wurfel
Journal:  Crit Care       Date:  2015-10-19       Impact factor: 9.097

7.  Successful treatment of Bronchiolitis obliterans with organizing pneumonia in dialysis patient.

Authors:  Vivek B Kute; Pankaj R Shah; Aruna V Vanikar; Manoj R Gumber; Himanshu V Patel; Sachin B Patil; Hargovind L Trivedi
Journal:  Indian J Crit Care Med       Date:  2012-07

8.  Function of the p38MAPK-HSP27 pathway in rat lung injury induced by acute ischemic kidney injury.

Authors:  Tao Ma; Xiao Wei Liu; Zhi Liu
Journal:  Biomed Res Int       Date:  2013-03-27       Impact factor: 3.411

Review 9.  Poly(ADP-Ribose)Polymerase-1 in Lung Inflammatory Disorders: A Review.

Authors:  Gurupreet S Sethi; Vivek Dharwal; Amarjit S Naura
Journal:  Front Immunol       Date:  2017-09-19       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.